At HemoClear, we create and offer innovative, practical medical devices for severe or life-threatening diseases with limited available or affordable treatment options. All devices that we bring are related to the use of blood and blood components.
Donor blood
Annually, 100 million blood transfusions with donor blood take place worldwide. A transfusion provides the part or parts of blood you need, with red blood cells being the most commonly transfused.
Despite its broad applicability, allogeneic (donor) red blood cell transfusion is still associated with;
- High costs per treatment due to donor blood purchase prices and hospital resource expenses.
- Health risks, resulting in medical complications, longer recovery time, or even mortality.
- Scarcity, ~30 million units are lacking in the middle- and low-income countries to meet minimal demand for this life-saving treatment.
Patient Blood Management (PBM) improves patient outcomes by enhancing medical and surgical regimes to conserve patients’ blood. Due to efficient management, patients require fewer transfusions of donated blood, thus avoiding transfusion-associated complications and costs. Using autologous, patient’s own, blood for transfusion is a valuable PBM tool to reduce donor blood dependence.
Autologous, patient own, blood
Autologous blood transfusion, blood transfusion with the patient’s own blood, is preferred in medical guidelines since It addresses the important implications of donor blood transfusion.
The autologous or cell-salvaged blood:
- quality is superior,
- matches the patient’s profile,
- is available in severe bleeding,
- can be prepared and transfused at a lower cost.
The prerequisite for autologous blood transfusion is that it is “washed” before reinfusion; essential components like red blood cells and platelets are captured while harmful agents and activated factors are washed out.
The current autologous blood preparation solutions, cell savers, capture red blood cells by centrifugal force and depend on equipment, expensive consumables, and trained operators. These necessities limit their availability and affordability and therefore limit autologous blood use. Platelets (thrombocytes) that help to stop bleeding are not captured in the centrifugal procedure and are consequently lost for autologous use.
HemoClear
HemoClear now boosts cell salvage options by introducing the first microfiltration cell salvage solution. In a straightforward and gravity-driven procedure, HemoClear generates platelet-rich transfusion blood that is:
- safe
- of the highest quality
- cost-efficient
With HemoClear, cell salvage can be performed everywhere and by any healthcare professional. The device is operational in a couple of minutes, while the entire bedside filter procedure takes less than 30 minutes. One HemoClear filter generates up to 8 units of high-quality autologous transfusion blood.
The innovative HemoClear microfiltration technology is of crucial importance in autologous blood transfusion. It accurately filters out contaminations and recuperates practically all functioning cells. In contrast to coarse filters and concentrator technologies, microfiltration provides high-quality and safe transfusion blood. Compared to centrifugal cell-saving technologies, HemoClear captures non-activated platelets in therapeutically relevant concentrations.
About us
The company history
HemoClear B.V. was founded in the Netherlands in 2015 as a spinoff company of Medical2Market B.V. Medical2Market is a medical device development company in which Arno Nierich, M.D., a Senior Consultant Cardiac Anesthesiologist-intensivist translates his daily work observations into innovative medical solutions.
HemoClear became fully operational in 2018 when Vincent Franssen joined the company as Chief Executive Officer.
Add Your Heading Text Here
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Team HemoClear onderscheidt zich:
- Belofte aan de klant
- Missie - Waar sta je voor en wat wil je uitdragen?
- List Item #3
Meet the HemoClear team
At HemoClear, we treasure and strive for the tremendous value coming from different opinions and insights from a wide variety of individuals of different ages, gender, ethnicity, education, physical abilities, races, and religions. We’re building an enthusiastic and highly motivated inclusive culture where every team member can thrive.
Vincent Franssen
Chief Executive Officer
Arno Nierich
Chief Medical Officer
Hein Kemperman
Chief Finance Officer
Dion Osemwengie
Global Business Development Manager
Colin Rutgers
Quality & Product Development Manager
